



Express Mail NO. 2687 US
Date of Deposit: October 9, 2007

Page 1 of 3
Attorney Docket No.: 21486-032

Please type a plus sign (+) in this box +

PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO		Application Number	09/436,184
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	November 8, 1999
(use as many sheets as necessary)		First Named Inventor	Wands
		Group Art Unit	1643
		Examiner Name	Karen A. Canella
		Attorney Docket Number	21486-032

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
A1		4,735,210	04/05/88	Goldenberg	128	654	
A2		5,660,827	08/26/97	Thorpe et al.	424	152.1	
A3		5,789,426	08/04/98	Hanauske-Abel et al.	514	348	
A4		5,814,500	09/29/98	Dietz	435	172.3	
A5		5,830,478	11/03/98	Raso et al.	424	236.1	
A6		5,851,999	12/22/98	Ullrich et al.	154	44	
A7		5,854,205	12/29/98	O'Reilly et al.	514	2	
A8		5,939,531	08/17/99	Wels et al.	530	387.3	
A9		6,165,464	12/26/00	Hudziak et al.	424	142.1	
A10		7,160,885 B2	01/09/07	Currie et al.	514	249	

U.S. PUBLISHED APPLICATION DOCUMENTS

Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
A11		2005/0113329 A1	05/26/05	Wands et al.	514	44	
A12		2005/0123545 A1	06/09/05	Wands et al.	424	146.1	
A13		2006/0211058 A1	09/21/06	Wands et al.	435	7.23	

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
B2	WO	98/19691		THE GENERAL HOSPITAL CORPORATION	05/14/98	
B3	WO	98/56387		UNISEARCH LIMITED	12/17/98	
B4	WO	99/01020		HUMAN GENOME SCIENCES, INC.	01/14/99	
B5	EP	0 180 188 A2		OTSUKA PHARMACEUTICALS CO., LTD.	05/07/86	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C44	Baron et al., "Insulin Receptor-Induced Phosphorylation of Cellular and Synthetic Substrates Is Regulated by the Receptor β -Subunit C-Terminus", <i>Endocrinol.</i> , 137(8) 3416-23 (1996)
	C45	Boder et al., "Directed Evolution of Antibody Fragments with Monovalent Femtomolar Antigen-Binding Affinity", <i>PNAS</i> , 97(20):10701-10705 (2000)
	C46	Boutin et al., <i>Differentiation Res. Biol. Diversity, Abstract only</i> , 48(2):99-105 (1991)
	C47	Clark, M., "Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man", Academic Titles, General Introduction, page 1 (1993)
	C48	De la Monte et al., "Aspartyl (Asparaginyl) Beta Hydroxylase (AAH) Expression Marks Invasiveness of Primary Malignant CNS Neoplasms", <i>Abstract only, Lab. Invest.</i> , 79(1):1000 (1999)
	C49	DeWys et al., "Studies on the Effect of Tumor Type and Route of Administration on the Antitumor Activity of the Amino Acid Mimosine (NSC-69188)", <i>Cancer Chemother. Rep.</i> , 57(1 – Part 1):41-49 (1973)
	C50	Dinchuk, et al., "Aspartyl β -Hydroxylase (Asph) and an Evolutionarily Conserved Isoform of Asph Missing the Catalytic Domain Share Exons with Junctin," <i>J. Biol. Chem.</i> , 275(50):39543-39554 (2000)
	C51	Dinchuk et al., "Absence of Post-translational Aspartyl β -Hydroxylation of Epidermal Growth Factor Domains in Mice Leads to Developmental Defects and an Increased Incidence of Intestinal Neoplasia", <i>J. Biol. Chem.</i> , 277(15):12970-12977 (2002)
	C52	Dorland's Pocket Medical Dictionary, 23 rd Edition, W.B. Saunders Co., page 246 (1982)
	C53	Foote et al., "Breaking the Affinity Ceiling for Antibodies and T Cell Receptors", <i>PNAS</i> , 97(20):10679-10681 (2000)
	C54	GENBANK Accession No. JS0670 (1999)
	C55	GENBANK Accession No. NM_005544 (2000)
	C56	GENBANK Accession No. S83325 (1997)
	C57	Goding, J. W., "Monoclonal Antibodies: Principles and Practice", pgs. 1-4 (1986)
	C58	Huse, W., <u>Antibody Engineering</u> , "Combinatorial Antibody Expression Libraries in Filamentous Phage", Chapter 5, pgs. 103-107 (1992)
	C59	Ince et al., "The Insulin Substrate-1 (HIRS-1) Signal Transduction Pathway Influences Expression on Human Aspartyl (Asparaginyl) Beta-Hydroxylase (HAAH) in Human Hepato-Cellular Carcinoma Cells", <i>Hepatol.</i> , Abstract #1398 , page 1398 (1999)
	C60	Kerr et al., "Common Immunological Techniques", <i>Immunochem. LabFax</i> , pg. 193 (1994)
	C61	Kieke et al., "Selection of Functional T Cell Receptor Mutants From a Yeast Surface-Display Library", <i>Proc. Natl. Acad. Sci. USA</i> , 96:5651-5656 (1999)
	C62	Lebowitz et al., "Human aspartyl (Asparaginyl) Beta-hydroxylase is a serum biomarker of breast, ovarian, and prostate cancer", <i>Proceedings of the American Association for Cancer Research, Abstract #2408</i> , 44:471 (2003)
	C63	Ogawa et al., "Role of binding proteins to IRS-1 in insulin signalling", <i>Mol. Cell. Biochem.</i> , 182:13-22 (1998)
	C64	Palumbo et al., "Human Aspartyl (Asparaginyl) Beta-Hydroxylase Monoclonal Antibodies: Potential Biomarkers for Pancreatic Carcinoma", <i>Pancreas</i> , 25(1):39-44 (2002)
	C65	Radosevich et al., "Monoclonal Antibody 44-3A6 as a Probe for a Novel Antigen Found on Human Lung Carcinomas with Glandular Differentiation", <i>Cancer Res.</i> , 45:5808-5812 (1985)
	C66	Schlom, J., "Monoclonal Antibodies: They're More and Less than You Think", <i>Mol. Foundations Oncol.</i> , Ed. S. Broder, pgs. 95-134 (1991).
	C67	Sepe et al., "Role of the Aspartyl-Asparaginyl-Beta-Hydroxylase Gene in Neuroblastoma Cell Motility", <i>Lab. Invest.</i> , 82(7):881-889 (2002)

	C68	Sinkule et al., „Monoclonal Antibody 44-3A6 Doxorubicin Immunoconjugates: Comparative in vitro Anti-Tumor Efficacy of Different Conjugation Methods”, <i>Tumor Biol.</i> , 12:198-206 (1991)
	C69	Spencer-Dene et al., <i>Gastroenterol.</i> , Abstract only , 130(4):1233-1244 (2006)
	C70	Teillac et al., <i>Annales d'Urologie</i> (France), English Abstract only , 24(1):37-41 (1990)
	C71	<i>The Sigma Catalog</i> , “Biochemicals and Reagents for Life Science Research”, pg. 729 (1997)
	C72	Tomida et al., <i>Anti-Cancer Drug Design</i> , Abstract only , 14(2):169-177 (1999)
	C73	Treves et al., “Molecular Cloning, Expression, Functional Characterization, Chromosomal Localization, and Gene Structure of Junctate, a Novel Integral Calcium Binding Protein of Sarco(endo)plasmic Reticulum Membrane”, 275(50):39555-39568 (2000)
	C74	Weg-Remers et al., „Soluble CD44 and CD44v6 Serum Levels in Patients with Colorectal Cancer are Independent of Tumor Stage and Tissue Expression of CD44v6”, <i>Am. J. Gastroenterol.</i> , 93(5):790-794 (1998)
	C75	White, M. F., “The IRS-signalling system: A network of docking proteins that mediate insulin action”, <i>Mol. Cell. Biochem.</i> , 182:3-11 (1998)
	C76	Wright et al., <i>J. Pathol.</i> , Abstract only , 162(4):279-284 (1990)
	C77	Xian et al., “Expression of aspartyl beta-hydroxylase and its clinicopathological significance in hepatocellular carcinoma”, <i>Modern Pathol.</i> , 19:280-286 (2006)

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.